Laura Bohn

Laura Bohn, Ph.D.

Chair And Professor, Department Of Molecular Medicine

Department: SR-MM-BOHN LAB
Business Phone: (561) 228-2227
Business Email: laura.bohn@ufl.edu

About Laura Bohn

Related Links:
Additional Positions:
Member at-large
2022 – Current · ASPET Publications Committee
Member
2021 – Current · Program Committee for Bioactive Lipids in Cancer, Inflammation and Related Diseases 2022
NIDA Board of Scientific Counselors, member
2020 – Current · National Institute on Drug Abuse
Chair
2017 – Current · IACUC and Use Committee, Florida Campus
Member
2014 – Current · Behavior Core Committee
Editorial Board
2013 – Current · Journal of Biological Chemistry
Chair
2012 – Current · Scripps Florida Theme Committee for Graduate Education Self Evaluation
Co-Organizer
2020 – 2020 · Keystone Conference 2020: Aligning the Target: Acute and Chronic Pain
Co-Chair
2019 – 2019 · Gordon Research Conference on Molecular Pharmacology
Co-Organizer
2019 – 2019 · Keystone Conferences “G Protein-Coupled Receptors: Structure, Signaling and Drug Discovery”
Scripps Research Bicoastal, Member
2018 – 2022 · Awards Committee
Member
2017 – 2021 · NIH Drug Discovery for the Nervous System Study Section
Bicoastal, Member
2016 – 2022 · Promotions and Tenure Committee
Member
2015 – 2017 · ASPET program committee
Co-Organizer
2014 – 2014 · Lorentz Workshop “Exploring the biology of GPCRs: bridging biochemistry, therapeutics and physiology.”
Professor (tenured), Molecular Therapeutics
2014 – 2017 · Scripps Research
Vice Chair
2013 – 2017 · IACUC
Chair, Neuropharmacology Division
2013 – 2015 · ASPET
Co-Organizer
2013 – 2013 · 4th GPCR Colloquium Following ASPET/Experimental Biology
MiniReview editor
2010 – 2013 · Molecular Pharmacology
Member
2009 – 2013 · NIH ZRG1 MDCN-Molecular Neuropharmacology and Signaling Study Section (MNPS)
Associate Professor (tenured), Molecular Therapeutics
2009 – 2014 · Scripps Research
Associate Professor (tenured, Joint Appointment), Neuroscience
2009 – 2014 · Scripps Research
Associate Professor (tenured), College of Medicine, Departments of Pharmacology and Psychiatry
2007 – 2009 · The Ohio State University
Assistant Professor, College of Medicine, Departments of Pharmacology and Psychiatry
2003 – 2007 · The Ohio State University
Assistant Research Professor, Department of Cell Biology
2002 – 2003 · Duke University Medical Center
Postdoctoral Scholar
1999 – 2002 ·

Accomplishments

Coy W. Waller Distinguished Lecture
2019 · University of Mississippi
Elected Chair
2019 · Gordon Conference on Molecular Pharmacology
The Charles E. Smith Annual Memorial Lecture
2019 · The National Institute for Psychobiology in Israel
“Visions in Pharmacology” Student-invited lecturer
2019 · University of Toronto
"America’s Opioid Epidemic”, Student-Invited Lecturer
2018 · Vanderbilt University
The Viktor Mutt Lectureship
2018 · International Regulatory Peptide Society
Student-Invited NIDA Distinguished Lecture
2017 · University of Texas Medical Branch
Student-Invited Opioid Crisis Symposium Keynote Speaker
2017 · West Virginia University
Dennis Feller Distinguished Lectureship
2016 · The Ohio State University College of Pharmacy
Distinguished Lecturer
2016 · Creighton University School of Medicine
John J. Abel Award
2011 · American Society of Pharmacology & Experimental Therapeutics and Pfizer
The Joseph Cochin Young Investigator Award
2009 · College on Problems of Drug Dependence
Featured as one of “30 in Their 30s”
2007 · The Voice of Bioscience in Ohio
Award for Excellence in Research
2005 · School of Biomedical Sciences at The Ohio State University
Committee on Women in Neuroscience Career Development Award
2005 · Society for Neuroscience and Merck
Early Career Investigator Award
2002 · College on Problems of Drug Dependence
Ruth L. Kirschstein National Research Service Award (NRSA) Postdoctoral Fellowship
2000-2002 · NIDA F32
Ruth L. Kirschstein National Research Service Award (NRSA) Predoctoral Fellowship
1996-1999 · NIDA F31

Research Profile

Research in the Bohn laboratory is focused on understanding how G protein-coupled receptors function in an endogenous setting to control physiologically relevant processes. We are most interested in receptors that mediate neurological functions, particularly those of the opioid, serotonin and cannabinoid families. Ultimately, our goal is to refine therapeutics- to enhance the benefits and eliminate the side effects. In this manner, we hope to inspire new approaches in treating pain, addiction and mood disorders.

The Bohn laboratory is most widely known for our work in opioid receptors. Early work while in the laboratory of Marc Caron and in collaboration with Robert Lefkowitz at Duke University indicated that barrestin2 plays a critical role in determining the physiological role of the mu opioid receptor (MOR) in vivo. Our laboratory has shown that barrestin2 plays different roles in regulating the MOR depending upon the physiological function assessed. This is very important as activation of the MOR results in multiple physiological processes ranging from the highly desirable suppression of pain perception to the deadly effects of respiratory failure. By determining which barrestin2-mediated signaling pathways are associated with these different physiological outcomes, we aim to elucidate a means to develop potent opioid analgesics that circumvent the adverse side effects. The bulk of our work to date suggests that if we preserve MOR coupling to G proteins, but eliminate the interactions between the receptor and the scaffolding protein, barrestin2, then we may be able to separate analgesic potency from constipation, respiratory suppression, tolerance and physical dependence.

Our lab is now focused on developing tool compounds that will allow us to test these hypotheses. Our agonists are designed, in collaboration with Dr. Tom Bannister of TSRI, to activate MOR in a manner that preserves or improves G protein signaling while eliminating the recruitment of barrestins. In addition to generating potential therapeutic leads, we are very interested in using these tools to elucidate MOR function in vivo. As we refine the pathways underlying different physiological responses, we will then know the signaling mechanisms to preserve and the ones to avoid.

We are also taking a similar approach with the kappa opioid receptors (KOR). The KOR in the midbrain acts to regulate dopamine and serotonin levels and thereby serves as an attractive target for modulating mood and reward thresholds. KOR ligands that display bias towards or against recruiting barrestins are of interest as barrestin2 has been implicated in facilitating aversive KOR-mediated behaviors. In our work with Dr. Jeff Aubé of Kansas University, we have been developing and evaluating KOR biased agonists to determine which physiologies are preserved or disrupted in mouse models. Since the KOR is involved in diverse physiological functions, compounds generated in this project may serve as interesting candidates for the treatment of depressive disorders and addiction. Moreover, KOR agonism produces antinociception and blocks itch and may also represent potential therapeutic avenues.

Recently, we have begun evaluating ligands for biased agonism among cannabinoid receptor (CB1 and CB2) agonists in collaboration with Dr. Alex Makriyannis at Northeastern University. Given the emerging implications for using cannabinoids as therapeutics for a wide-range of disorders, there are many opportunities for new drug development. This collaboration has also involved working with Dr. Ray Stevens (USC) and Dr. James Liu (Shanghai Tech) to solve the first crystal structures of antagonist and agonist bound CB1 receptors. Additional efforts in the laboratory focus on evaluating how antipsychotic drugs and mood altering neurotransmitters such as serotonin act at serotonin receptors.

Since the receptors described above are involved in modulating mood, motivation, and sensory perception, it stands to reason that our laboratory is most interested in developing means to treat pain, whether due to injury, disease or mental state, in a manner that adequately manages the pain, without causing deabilitating side effects.

Open Researcher and Contributor ID (ORCID)

0000-0002-6474-8179

Publications

2022
Advances in Sulfonamide Kappa Opioid Receptor Antagonists: Structural Refinement and Evaluation of CNS Clearance
ACS Chemical Neuroscience. 13(8):1315-1332 [DOI] 10.1021/acschemneuro.2c00140.
2022
Community guidelines for GPCR ligand bias: IUPHAR review 32
British Journal of Pharmacology. 179(14):3651-3674 [DOI] 10.1111/bph.15811. [PMID] 35106752.
2022
Improved cyclobutyl nabilone analogs as potent CB1 receptor agonists
European Journal of Medicinal Chemistry. 230 [DOI] 10.1016/j.ejmech.2021.114027.
2021
A Genetically Encoded F-19 NMR Probe Reveals the Allosteric Modulation Mechanism of Cannabinoid Receptor 1
Journal of the American Chemical Society. 143(40):16320-16325 [DOI] 10.1021/jacs.1c06847.
2021
Comparison of morphine, oxycodone and the biased MOR agonist SR-17018 for tolerance and efficacy in mouse models of pain.
Neuropharmacology. 185 [DOI] 10.1016/j.neuropharm.2020.108439. [PMID] 33345829.
2021
Decaf or regular? Energizing the caffeine receptor.
Cell. 184(7):1659-1660 [DOI] 10.1016/j.cell.2021.03.016. [PMID] 33798438.
2021
G protein signaling–biased mu opioid receptor agonists that produce sustained G protein activation are noncompetitive agonists
Proceedings of the National Academy of Sciences. 118(48) [DOI] 10.1073/pnas.2102178118. [PMID] 34819362.
2021
Low Intrinsic Efficacy Alone Cannot Explain the Improved Side Effect Profiles of New Opioid Agonists
Biochemistry. [DOI] 10.1021/acs.biochem.1c00466. [PMID] 34468132.
2021
Novel Functionalized Cannabinoid Receptor Probes: Development of Exceptionally Potent Agonists.
Journal of medicinal chemistry. 64(7):3870-3884 [DOI] 10.1021/acs.jmedchem.0c02053. [PMID] 33761251.
2021
Some effects of putative G-protein biased mu-opioid receptor agonists in male rhesus monkeys.
Behavioural pharmacology. 32(5):453-458 [DOI] 10.1097/FBP.0000000000000634. [PMID] 33883450.
2020
A G protein signaling-biased agonist at the μ-opioid receptor reverses morphine tolerance while preventing morphine withdrawal.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 45(2):416-425 [DOI] 10.1038/s41386-019-0491-8. [PMID] 31443104.
2020
Activation and Signaling Mechanism Revealed by Cannabinoid Receptor-Gi Complex Structures.
Cell. 180(4):655-665.e18 [DOI] 10.1016/j.cell.2020.01.008. [PMID] 32004463.
2020
Arrestin recruitment to dopamine D2 receptor mediates locomotion but not incentive motivation.
Molecular psychiatry. 25(9):2086-2100 [DOI] 10.1038/s41380-018-0212-4. [PMID] 30120413.
2020
Toward Directing Opioid Receptor Signaling to Refine Opioid Therapeutics.
Biological psychiatry. 87(1):15-21 [DOI] 10.1016/j.biopsych.2019.10.020. [PMID] 31806082.
2019
Crystal Structure of the Human Cannabinoid Receptor CB2.
Cell. 176(3):459-467.e13 [DOI] 10.1016/j.cell.2018.12.011. [PMID] 30639103.
2019
Probing the CB1 Cannabinoid Receptor Binding Pocket with AM6538, a High-Affinity Irreversible Antagonist.
Molecular pharmacology. 96(5):619-628 [DOI] 10.1124/mol.119.116483. [PMID] 31515283.
2019
Quantitating Ligand Bias Using the Competitive Model of Ligand Activity.
Methods in molecular biology (Clifton, N.J.). 1957:235-247 [DOI] 10.1007/978-1-4939-9158-7_15. [PMID] 30919358.
2018
G protein signaling–biased agonism at the κ-opioid receptor is maintained in striatal neurons
Science Signaling. 11(542) [DOI] 10.1126/scisignal.aar4309. [PMID] 30087177.
2018
O6C-20-nor-salvinorin A is a stable and potent KOR agonist.
Bioorganic & medicinal chemistry letters. 28(16):2770-2772 [DOI] 10.1016/j.bmcl.2018.01.055. [PMID] 29426768.
2018
Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias.
Journal of medicinal chemistry. 61(19):8895-8907 [DOI] 10.1021/acs.jmedchem.8b01136. [PMID] 30199635.
2018
Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists.
ACS omega. 3(10):12658-12678 [DOI] 10.1021/acsomega.8b01237. [PMID] 30411015.
2018
The effect of quinine in two bottle choice procedures in C57BL6 mice: Opioid preference, somatic withdrawal, and pharmacokinetic outcomes.
Drug and alcohol dependence. 191:195-202 [DOI] 10.1016/j.drugalcdep.2018.05.034. [PMID] 30138791.
2017
Approaches to Assess Biased Signaling at the CB1R Receptor.
Methods in enzymology. 593:259-279 [DOI] 10.1016/bs.mie.2017.06.031. [PMID] 28750807.
2017
Bias Factor and Therapeutic Window Correlate to Predict Safer Opioid Analgesics.
Cell. 171(5):1165-1175.e13 [DOI] 10.1016/j.cell.2017.10.035. [PMID] 29149605.
2017
Correction to “Structure-Activity Relationship Studies of Functionally Selective Kappa Opioid Receptor Agonists that Modulate ERK 1/2 Phosphorylation While Preserving G Protein Over βArrestin2 Signaling Bias”.
ACS chemical neuroscience. 8(7) [DOI] 10.1021/acschemneuro.7b00157. [PMID] 28541028.
2017
Crystal structures of agonist-bound human cannabinoid receptor CB1.
Nature. 547(7664):468-471 [DOI] 10.1038/nature23272. [PMID] 28678776.
2017
Dynamic Strategic Bond Analysis Yields a Ten-Step Synthesis of 20-nor-Salvinorin A, a Potent κ-OR Agonist.
ACS central science. 3(12):1329-1336 [DOI] 10.1021/acscentsci.7b00488. [PMID] 29296674.
2017
Seeking (and Finding) Biased Ligands of the Kappa Opioid Receptor.
ACS medicinal chemistry letters. 8(7):694-700 [DOI] 10.1021/acsmedchemlett.7b00224. [PMID] 28740600.
2017
Stolonidiol: Synthesis, Target Identification, and Mechanism for Choline Acetyltransferase Activation.
Journal of the American Chemical Society. 139(16):5865-5869 [DOI] 10.1021/jacs.7b01083. [PMID] 28414442.
2016
5-HT1A Autoreceptors in the Dorsal Raphe Nucleus Convey Vulnerability to Compulsive Cocaine Seeking.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 41(5):1210-22 [DOI] 10.1038/npp.2015.268. [PMID] 26324408.
2016
Biased agonism: An emerging paradigm in GPCR drug discovery.
Bioorganic & medicinal chemistry letters. 26(2):241-250 [DOI] 10.1016/j.bmcl.2015.12.024. [PMID] 26707396.
2016
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria.
Science signaling. 9(456) [PMID] 27899527.
2016
Crystal Structure of the Human Cannabinoid Receptor CB1.
Cell. 167(3):750-762.e14 [DOI] 10.1016/j.cell.2016.10.004. [PMID] 27768894.
2016
RasGRP1 promotes amphetamine-induced motor behavior through a Rhes interaction network (“Rhesactome”) in the striatum.
Science signaling. 9(454) [PMID] 27902448.
2016
Recruitment of β-Arrestin into Neuronal Cilia Modulates Somatostatin Receptor Subtype 3 Ciliary Localization.
Molecular and cellular biology. 36(1):223-35 [DOI] 10.1128/MCB.00765-15. [PMID] 26503786.
2016
Synthesis of Kappa Opioid Antagonists Based On Pyrrolo[1,2-α]quinoxalinones Using an N-Arylation/Condensation/Oxidation Reaction Sequence.
The Journal of organic chemistry. 81(21):10538-10550 [PMID] 27399050.
2016
Synthetic Ligands of Cannabinoid Receptors Affect Dauer Formation in the Nematode Caenorhabditis elegans.
G3 (Bethesda, Md.). 6(6):1695-705 [DOI] 10.1534/g3.116.026997. [PMID] 27172180.
2015
A novel method for analyzing extremely biased agonism at G protein-coupled receptors.
Molecular pharmacology. 87(5):866-77 [DOI] 10.1124/mol.114.096503. [PMID] 25680753.
2015
Approaches to Assess Functional Selectivity in GPCRs: Evaluating G Protein Signaling in an Endogenous Environment.
Methods in molecular biology (Clifton, N.J.). 1335:177-89 [DOI] 10.1007/978-1-4939-2914-6_12. [PMID] 26260601.
2015
Characterization of kappa opioid receptor mediated, dynorphin-stimulated [35S]GTPγS binding in mouse striatum for the evaluation of selective KOR ligands in an endogenous setting.
Neuropharmacology. 99:131-41 [DOI] 10.1016/j.neuropharm.2015.07.001. [PMID] 26160155.
2015
Exploring the Biology of G Protein-Coupled Receptors from In Vitro to In Vivo.
Molecular pharmacology. 88(3):534-5 [DOI] 10.1124/mol.115.100750. [PMID] 26162863.
2015
Fulfilling the Promise of “Biased” G Protein-Coupled Receptor Agonism.
Molecular pharmacology. 88(3):579-88 [DOI] 10.1124/mol.115.099630. [PMID] 26134495.
2015
Investigation of the role of βarrestin2 in kappa opioid receptor modulation in a mouse model of pruritus.
Neuropharmacology. 99:600-9 [DOI] 10.1016/j.neuropharm.2015.08.027. [PMID] 26318102.
2015
Molecular-interaction and signaling profiles of AM3677, a novel covalent agonist selective for the cannabinoid 1 receptor.
ACS chemical neuroscience. 6(8):1400-10 [DOI] 10.1021/acschemneuro.5b00090. [PMID] 25978068.
2015
Potency enhancement of the κ-opioid receptor antagonist probe ML140 through sulfonamide constraint utilizing a tetrahydroisoquinoline motif.
Bioorganic & medicinal chemistry. 23(14):3948-56 [DOI] 10.1016/j.bmc.2014.12.033. [PMID] 25593096.
2015
Structure-activity relationship studies of functionally selective kappa opioid receptor agonists that modulate ERK 1/2 phosphorylation while preserving G protein over βarrestin2 signaling bias.
ACS chemical neuroscience. 6(8):1411-9 [DOI] 10.1021/acschemneuro.5b00092. [PMID] 25891774.
2014
Clozapine acts as an agonist at serotonin 2A receptors to counter MK-801-induced behaviors through a βarrestin2-independent activation of Akt.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 39(8):1902-13 [DOI] 10.1038/npp.2014.38. [PMID] 24531562.
2014
Functional selectivity of GPCR signaling in animals.
Current opinion in cell biology. 27:102-8 [DOI] 10.1016/j.ceb.2013.11.010. [PMID] 24680435.
2014
β-arrestins: regulatory role and therapeutic potential in opioid and cannabinoid receptor-mediated analgesia.
Handbook of experimental pharmacology. 219:427-43 [DOI] 10.1007/978-3-642-41199-1_22. [PMID] 24292843.
2013
Development of functionally selective, small molecule agonists at kappa opioid receptors.
The Journal of biological chemistry. 288(51):36703-16 [DOI] 10.1074/jbc.M113.504381. [PMID] 24187130.
2013
Functional selectivity of 6′-guanidinonaltrindole (6′-GNTI) at κ-opioid receptors in striatal neurons.
The Journal of biological chemistry. 288(31):22387-98 [DOI] 10.1074/jbc.M113.476234. [PMID] 23775075.
2012
Antinociceptive effects of herkinorin, a MOP receptor agonist derived from salvinorin A in the formalin test in rats: new concepts in mu opioid receptor pharmacology: from a symposium on new concepts in mu-opioid pharmacology.
Drug and alcohol dependence. 121(3):181-8 [DOI] 10.1016/j.drugalcdep.2011.10.026. [PMID] 22119134.
2012
Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues.
Bioorganic & medicinal chemistry letters. 22(2):1023-6 [DOI] 10.1016/j.bmcl.2011.11.128. [PMID] 22204910.
2012
Discovery of Small Molecule Kappa Opioid Receptor Agonist and Antagonist Chemotypes through a HTS and Hit Refinement Strategy.
ACS chemical neuroscience. 3(3):221-236 [PMID] 22737280.
2012
GIRK channel modulation by assembly with allosterically regulated RGS proteins.
Proceedings of the National Academy of Sciences of the United States of America. 109(49):19977-82 [DOI] 10.1073/pnas.1214337109. [PMID] 23169654.
2012
β-arrestin2 regulates cannabinoid CB1 receptor signaling and adaptation in a central nervous system region-dependent manner.
Biological psychiatry. 71(8):714-24 [DOI] 10.1016/j.biopsych.2011.11.027. [PMID] 22264443.
2011
Agonist-directed interactions with specific beta-arrestins determine mu-opioid receptor trafficking, ubiquitination, and dephosphorylation.
The Journal of biological chemistry. 286(36):31731-41 [DOI] 10.1074/jbc.M111.248310. [PMID] 21757712.
2011
Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance.
Pharmacological reviews. 63(4):1001-19 [DOI] 10.1124/pr.111.004598. [PMID] 21873412.
2011
Lubiprostone reverses the inhibitory action of morphine on mucosal secretion in human small intestine.
Digestive diseases and sciences. 56(2):330-8 [DOI] 10.1007/s10620-010-1515-8. [PMID] 21181441.
2011
Synthesis of conolidine, a potent non-opioid analgesic for tonic and persistent pain.
Nature chemistry. 3(6):449-53 [DOI] 10.1038/nchem.1050. [PMID] 21602859.
2011
The role of beta-arrestin2 in the severity of antinociceptive tolerance and physical dependence induced by different opioid pain therapeutics.
Neuropharmacology. 60(1):58-65 [DOI] 10.1016/j.neuropharm.2010.08.003. [PMID] 20713067.
2010
Lubiprostone reverses the inhibitory action of morphine on intestinal secretion in guinea pig and mouse.
The Journal of pharmacology and experimental therapeutics. 334(1):333-40 [DOI] 10.1124/jpet.110.166116. [PMID] 20406855.
2010
Seeking Ligand Bias: Assessing GPCR Coupling to Beta-Arrestins for Drug Discovery.
Drug discovery today. Technologies. 7(1):e37-e42 [PMID] 21218149.
2010
Serotonin receptor signaling and regulation via β-arrestins.
Critical reviews in biochemistry and molecular biology. 45(6):555-66 [DOI] 10.3109/10409238.2010.516741. [PMID] 20925600.
2010
Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a ß-arrestin2/Src/Akt signaling complex in vivo.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 30(40):13513-24 [DOI] 10.1523/JNEUROSCI.1665-10.2010. [PMID] 20926677.
2009
Morphine-induced physiological and behavioral responses in mice lacking G protein-coupled receptor kinase 6.
Drug and alcohol dependence. 104(3):187-96 [DOI] 10.1016/j.drugalcdep.2009.04.011. [PMID] 19497686.
2009
Pharmacological characterization of a selective agonist for bombesin receptor subtype-3.
Biochemical and biophysical research communications. 387(2):283-8 [DOI] 10.1016/j.bbrc.2009.07.006. [PMID] 19580790.
2009
Physiological and pharmacological implications of beta-arrestin regulation.
Pharmacology & therapeutics. 121(3):285-93 [DOI] 10.1016/j.pharmthera.2008.11.005. [PMID] 19100766.
2009
Stimulation of mucosal secretion by lubiprostone (SPI-0211) in guinea pig small intestine and colon.
American journal of physiology. Gastrointestinal and liver physiology. 296(4):G823-32 [DOI] 10.1152/ajpgi.90447.2008. [PMID] 19179625.
2008
Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo.
Proceedings of the National Academy of Sciences of the United States of America. 105(3):1079-84 [DOI] 10.1073/pnas.0708862105. [PMID] 18195357.
2008
Herkinorin analogues with differential beta-arrestin-2 interactions.
Journal of medicinal chemistry. 51(8):2421-31 [DOI] 10.1021/jm701162g. [PMID] 18380425.
2008
Kappa opioids promote the proliferation of astrocytes via Gbetagamma and beta-arrestin 2-dependent MAPK-mediated pathways.
Journal of neurochemistry. 107(6):1753-65 [DOI] 10.1111/j.1471-4159.2008.05745.x. [PMID] 19014370.
2008
Post-activation-mediated changes in opioid receptors detected by N-terminal antibodies.
The Journal of biological chemistry. 283(16):10735-44 [DOI] 10.1074/jbc.M709454200. [PMID] 18256033.
2007
A comparison of noninternalizing (herkinorin) and internalizing (DAMGO) mu-opioid agonists on cellular markers related to opioid tolerance and dependence.
Synapse (New York, N.Y.). 61(3):166-75 [PMID] 17152090.
2007
An opioid agonist that does not induce mu-opioid receptor–arrestin interactions or receptor internalization.
Molecular pharmacology. 71(2):549-57 [PMID] 17090705.
2007
Constitutive trafficking–more than just running in circles?
Molecular pharmacology. 71(4):957-8 [PMID] 17251327.
2006
How specific are “target-specific” drugs? Celecoxib as a case in point.
Molecular interventions. 6(4):196-8 [PMID] 16960141.
2006
Opioid receptor signaling: relevance for gastrointestinal therapy.
Current opinion in pharmacology. 6(6):559-63 [PMID] 16935560.
2005
Characterization of conditioned place preference to cocaine in congenic dopamine transporter knockout female mice.
Psychopharmacology. 180(3):408-13 [PMID] 15719221.
2005
Morphine side effects in beta-arrestin 2 knockout mice.
The Journal of pharmacology and experimental therapeutics. 314(3):1195-201 [PMID] 15917400.
2005
Mu opioid receptor regulation and opiate responsiveness.
The AAPS journal. 7(3):E587-91 [PMID] 16353937.
2005
Opioid receptor homo- and heterodimerization in living cells by quantitative bioluminescence resonance energy transfer.
Molecular pharmacology. 67(6):2173-84 [PMID] 15778451.
2004
Desensitization of G protein-coupled receptors and neuronal functions.
Annual review of neuroscience. 27:107-44 [PMID] 15217328.
2004
Drosophila CG8422 encodes a functional diuretic hormone receptor.
The Journal of experimental biology. 207(Pt 5):743-8 [PMID] 14747406.
2004
G protein-coupled receptor kinase/beta-arrestin systems and drugs of abuse: psychostimulant and opiate studies in knockout mice.
Neuromolecular medicine. 5(1):41-50 [PMID] 15001811.
2004
Relative opioid efficacy is determined by the complements of the G protein-coupled receptor desensitization machinery.
Molecular pharmacology. 66(1):106-12 [PMID] 15213301.
2003
Dopaminergic supersensitivity in G protein-coupled receptor kinase 6-deficient mice.
Neuron. 38(2):291-303 [PMID] 12718862.
2003
Enhanced rewarding properties of morphine, but not cocaine, in beta(arrestin)-2 knock-out mice.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 23(32):10265-73 [PMID] 14614085.
2003
Identification of Drosophila neuropeptide receptors by G protein-coupled receptors-beta-arrestin2 interactions.
The Journal of biological chemistry. 278(52):52172-8 [PMID] 14555656.
2003
Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons.
Proceedings of the National Academy of Sciences of the United States of America. 100(19):11035-40 [PMID] 12958210.
2002
Apparent loss-of-function mutant GPCRs revealed as constitutively desensitized receptors.
Biochemistry. 41(40):11981-9 [PMID] 12356298.
2002
Differential mechanisms of morphine antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 22(23):10494-500 [PMID] 12451149.
2001
Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter.
Proceedings of the National Academy of Sciences of the United States of America. 98(20):11047-54 [PMID] 11572967.
2000
Mice lacking the norepinephrine transporter are supersensitive to psychostimulants.
Nature neuroscience. 3(5):465-71 [PMID] 10769386.
2000
Mitogenic signaling via endogenous kappa-opioid receptors in C6 glioma cells: evidence for the involvement of protein kinase C and the mitogen-activated protein kinase signaling cascade.
Journal of neurochemistry. 74(2):564-73 [PMID] 10646507.
2000
Mu-opioid agonist inhibition of kappa-opioid receptor-stimulated extracellular signal-regulated kinase phosphorylation is dynamin-dependent in C6 glioma cells.
Journal of neurochemistry. 74(2):574-81 [PMID] 10646508.
2000
Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence.
Nature. 408(6813):720-3 [PMID] 11130073.
2000
Potentiated opioid analgesia in norepinephrine transporter knock-out mice.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 20(24):9040-5 [PMID] 11124980.
1999
Enhanced morphine analgesia in mice lacking beta-arrestin 2.
Science (New York, N.Y.). 286(5449):2495-8 [PMID] 10617462.
1999
Muscarinic supersensitivity and impaired receptor desensitization in G protein-coupled receptor kinase 5-deficient mice.
Neuron. 24(4):1029-36 [PMID] 10624964.
1999
Requirement of receptor internalization for opioid stimulation of mitogen-activated protein kinase: biochemical and immunofluorescence confocal microscopic evidence.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 19(1):56-63 [PMID] 9870938.
1998
Brain opioid receptor adaptation and expression after prenatal exposure to buprenorphine.
Brain research. Developmental brain research. 111(1):35-42 [PMID] 9804882.
1998
Evidence for kappa- and mu-opioid receptor expression in C6 glioma cells.
Journal of neurochemistry. 70(5):1819-25 [PMID] 9572265.
1998
Kappa-opioid receptor binding varies inversely with tumor grade in human gliomas.
Cancer. 83(12):2561-6 [PMID] 9874464.
Comparison of morphine, oxycodone and the biased MOR agonist SR-17018 for tolerance and efficacy in mouse models of pain
. [DOI] 10.1101/2020.10.16.341776.
Low intrinsic efficacy alone cannot explain the improved side effect profiles of new opioid agonists
. [DOI] 10.1101/2020.11.19.390518.

Grants

Apr 2022 ACTIVE
Biased Kappa Opioid Agonists as Non-addictive Analgesics
Role: Principal Investigator
Funding: WAKE FOREST UNIV via NATL INST OF HLTH NIDA
Apr 2022 ACTIVE
Opioid Impacts on T Cell Pathways and Epigenetics to Modulate HIV Integration, Latency and Reservoirs
Role: Principal Investigator
Funding: UNIV OF CALIFORNIA SAN DIEGO via NATL INST OF HLTH NIDA
Apr 2022 ACTIVE
Pharmacological interactions between conventional and biased MOR agonists
Role: Principal Investigator
Funding: NATL INST OF HLTH NIDA
Apr 2022 ACTIVE
Synthesis and Evaluation of Functionally Biased Opioid Analgesics
Role: Principal Investigator
Funding: NATL INST OF HLTH NIDA
Apr 2022 ACTIVE
Structure and Function of CB2 Receptor
Role: Principal Investigator
Funding: NORTHEASTERN UNIV via NATL INST OF HLTH NIDA

Education

Ph.D. in Biochemistry & Molecular Biology
1999 · Saint Louis University, School of Medicine
Bachelor's of Arts in Chemistry
1993 · Virginia Polytechnic Institute and State University
Bachelor's of Science in Biochemistry
1993 · Virginia Polytechnic Institute and State University

Contact Details

Phones:
Business:
(561) 228-2227
Emails:
Business:
laura.bohn@ufl.edu
Addresses:
Business Mailing:
120 SCRIPPS WAY
JUPITER FL 33458